MedTrace Logo

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

NCT02615496 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 716

Last updated 2017-09-15

No results posted yet for this study

Summary

The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.

Conditions

  • Macular Degeneration

Interventions

BEHAVIORAL

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.

BEHAVIORAL

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet "Your guide to EYLEA," patient information leaflet, and audio CD.

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-07
Primary Completion
2016-09-30
Completion
2017-01-31

Countries

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615496 on ClinicalTrials.gov